3 results
Approved WMORecruiting
To test whether the proportion of patients in remission during the last 6 months of follow up is higher for a T2T strategy compared to a T2S stop strategy.
Approved WMOCompleted
This is an exploratory study to assess changes in colonic inflammation after 8 weeks of treatment with tofacitinib (XELJANZ) 2 x 5 mg BID in patients with moderate to severely active UC.
Approved WMORecruiting
The GO TEST OVERTURE study aims to demonstrate the superiority of the Treat to Target management strategy over a Treat to Avoid Symptoms approach in terms of clinical remission of gout symptoms.